Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.

MLA

Lai, C. L., et al. “Recombinant Α2 Interferon Is Superior to Doxorubicin for Inoperable Hepatocellular Carcinoma: A Prospective Randomised Trial.” British Journal of Cancer, vol. 60, no. 6, Dec. 1989, pp. 928–33. EBSCOhost, https://doi.org/10.1038/bjc.1989.392.

APA

Lai, C.-L., Wu, P.-C., Lok, A.-F., Lin, H.-J., Ngan, H., Lau, J.-N., Chung, H.-T., Ng, M.-T., Yeoh, E.-K., & Arnold, M. (1989). Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. British Journal of Cancer, 60(6), 928–933. https://doi.org/10.1038/bjc.1989.392

Chicago

Lai, C-L, P-C Wu, As-F Lok, H-J Lin, H Ngan, Jy-N Lau, H-T Chung, Mm-T Ng, E-K Yeoh, and M Arnold. 1989. “Recombinant Α2 Interferon Is Superior to Doxorubicin for Inoperable Hepatocellular Carcinoma: A Prospective Randomised Trial.” British Journal of Cancer 60 (6): 928–33. doi:10.1038/bjc.1989.392.